Location and allocation
Authors:
- Thierry ArtznerTAThierry Artzner
- William BernalWBWilliam Bernal
- Luca S BelliLBLuca S Belli
- Sara ContiSCSara Conti
- Paolo A CortesiPCPaolo A Cortesi
- Sophie-Caroline SacleuxSSSophie-Caroline Sacleux
- George-Philippe PageauxGPGeorge-Philippe Pageaux
- Sylvie RadenneSRSylvie Radenne
- Jonel TrebickaJTJonel Trebicka
- Javier FernandezJFJavier Fernandez
- Giovanni PerriconeGPGiovanni Perricone
- Salvatore PianoSPSalvatore Piano
- 1 September 2022
- journal article
- research article
- Published by Wolters Kluwer Health in Liver Transplantation
- Vol. 28 (9) , 1429-1440
Abstract
There is growing evidence that liver transplantation (LT) is the most effective treatment for acute-on-chronic liver failure grade-3 (ACLF-3). This study examines whether and how this evidence translates into practice by analyzing the variability in intensive care unit (ICU) admissions, listing strategies, and LT activity for patients with ACLF-3 across transplantation centers in Europe. Consecutive patients who were admitted to the ICU with ACLF-3, whether or not they were listed and/or transplanted with ACLF-3, between 2018 and 2019 were included across 20 transplantation centers. A total of 351 patients with ACLF-3 were included: 33 had been listed prior to developing ACLF-3 and 318 had not been listed at the time of admission to the ICU. There was no correlation between the number of unlisted patients with ACLF-3 admitted to the ICU and the number listed or transplanted while in ACLF-3 across centers. By contrast, there was a correlation between the number of patients listed and the number transplanted while in ACLF-3. About 21% of patients who were listed while in ACLF-3 died on the waiting list or were delisted. The percentage of LT for patients with ACLF-3 varied from 0% to 29% for those transplanted with decompensated cirrhosis across centers (average = 8%), with an I2 index of 68% (95% confidence interval, 49%-80%), showing substantial heterogeneity among centers. The 1-year survival for all patients with ACLF-3 was significantly higher in centers that listed and transplanted more patients with ACLF-3 (>10 patients) than in centers that listed and transplanted fewer: 36% versus 20%, respectively (p = 0.012). Patients with ACLF-3 face inequity of access to LT across Europe. Waitlisting strategies for patients with ACLF-3 influence their access to LT and, ultimately, their survival.Keywords
This publication has 13 references indexed in Scilit:
- Longterm Outcomes of Patients Undergoing Liver Transplantation for Acute‐on‐Chronic Liver FailureLiver Transplantation, 2020
- Systematic review with meta‐analysis: liver transplant provides survival benefit in patients with acute on chronic liver failureAlimentary Pharmacology & Therapeutics, 2020
- Liver transplantation for critically ill cirrhotic patients: Stratifying utility based on pretransplant factorsAmerican Journal of Transplantation, 2020
- Factors Associated with Survival of Patients With Severe Acute-On-Chronic Liver Failure Before and After Liver TransplantationGastroenterology, 2019
- Liver transplantation for critically ill cirrhotic patients: Overview and pragmatic proposalsWorld Journal of Gastroenterology, 2018
- Liver transplantation in patients with multiple organ failures: Feasibility and outcomesJournal of Hepatology, 2018
- Liver transplantation in critically ill patients: Preoperative predictive factors of post‐transplant mortality to avoid futilityClinical Transplantation, 2017
- Liver transplantation in the most severely ill cirrhotic patients: A multicenter study in acute-on-chronic liver failure grade 3Journal of Hepatology, 2017
- Impact of acute‐on‐chronic liver failure on 90‐day mortality following a first liver transplantationLiver International, 2017
- Acute-on-Chronic Liver Failure Is a Distinct Syndrome That Develops in Patients With Acute Decompensation of CirrhosisGastroenterology, 2013